NCT03815682: TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Any tumor that has potential to respond to immunotherapy is eligible
Exclusions: Patients with active, symptomatic, unstable, untreated central nervous system (CNS) disease – see trial for details; Patients with prior treatment of CAR T-cell therapy

Comments are closed.

Up ↑